PC
AZN icon

Parrish Capital’s AstraZeneca AZN Stock Holding History

Parrish Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.84M Sell
9,687
-1,868
-16% -$351K 1.77% 13
2026
Q1 		$2.28M Sell
11,555
-1,278
-10% -$246K 2.03% 8
2025
Q4 		$2.36M Buy
+12,833
New +$2.25M 2.14% 7

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Parrish Capital's AZN Position: Q2 2026 in Review

Parrish Capital reduced its AstraZeneca (AZN) stake by 16% in Q2 2026, selling an estimated $351K and leaving 9,687 shares worth $1.84M. The position accounts for 1.77% of the portfolio, ranked #13.

Parrish Capital first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.36M in Q4 2025. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Parrish Capital held 9,687 shares of AstraZeneca worth $1.84M as of Q2 2026.
  • Parrish Capital sold 1,868 AstraZeneca shares in Q2 2026, an estimated $351K.
  • AstraZeneca made up 1.77% of Parrish Capital's portfolio in Q2 2026, its #13 holding.
  • Parrish Capital first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
  • Parrish Capital's AstraZeneca position peaked at $2.36M in Q4 2025.
  • 1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Parrish Capital's 13F filing for Q2 2026, filed 1 Sep 2026.